Successful desensitization for cytarabine induced anaphylaxis.
10.4168/aard.2014.2.5.394
- Author:
Hyun Woo LEE
1
;
Jae Yong PARK
;
Joon Ho MOON
;
Kyung Taek PARK
;
Han Ki PARK
;
Hye Ryun KANG
Author Information
1. Department of Internal Medicine, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. helenmed@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Anaphylaxis;
Cytarabine;
Immunologic desensitization
- MeSH:
Adult;
Aged;
Anaphylaxis*;
Chlorpheniramine;
Cytarabine*;
Desensitization, Immunologic;
Drug Therapy;
Female;
Fever;
Humans;
Hydrocortisone;
Hypersensitivity;
Hypotension;
Leukemia;
Leukemia, Myeloid, Acute;
Lymphoma;
Premedication
- From:Allergy, Asthma & Respiratory Disease
2014;2(5):394-397
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cytarabine is a very important chemotherapeutic agent for leukemia and lymphoma patients and is prescribed more frequently than before. Cytarabine-induced delayed-onset hypersensitivity may rarely present as non-IgE mediated anaphylaxis. However, we do not know yet whether desensitization therapy in adults may be effective in cytarabine-induced delayed-onset anaphylaxis. A 78-year-old woman who was diagnosed with acute myeloblastic leukemia had chemotherapy including cytarabine. In spite of premedication with hydrocortisone and chlorpheniramine, the patient had anaphylaxis a few hours after cytarabine infusion. We decided to perform desensitization therapy. After desensitization therapy using a newly designed protocol, the patient was tolerable to cytarabine infusion without hypotension or high fever. Desensitization therapy was successfully performed on an adult patient with delayed-onset anaphylaxis caused by cytarabine.
